# Evgen Pharma plc The clinical significance of SFX-01

- Link: https://www.directorstalkinterviews.com/evgen-pharma-plc-the-clinical-significance-of-sfx-01/412758606
- Published: 2018-09-18T07:03:50+01:00
- Author: Giles Arbor

**Evgen Pharma plc** (LON:EVG), a clinical stage drug development company focused
on the treatment of cancer and neurological conditions, is today holding an Investor
Symposium for investors and analysts at the offices of Buchanan, 107 Cheapside, 
London EC2V 6DN.

The Investor Symposium, titled “The clinical significance of SFX-01” will begin 
at 9.15am. If you wish to attend the event, please contact Buchanan on 0207 466 
500 or email tillya@buchanan.uk.com

The presentations from the event will be made available on the Company website, 
www.evgen.com. No new material trading information will be disclosed.

Evgen Pharma plc is a clinical stage drug development company whose lead programmes
are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company’s
core technology is Sulforadex®, a method for synthesising and stabilising the naturally
occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic sulforaphane and
alpha-cyclodextrin.

Share on:
